Figure 1: Liver tumors in
c-Jun~Fra-2hepmice
A. Liver morphology and histology in a
c-Jun~Fra-2hep and representative
control mouse. Bar = 1 cm (top) and 100µm (H&E, bottom), tumors (T) are
indicated by arrows and dotted line. B. Serum protein induced
by vitamin K absence or antagonist-II (PIVKA), also known as
des-gamma-carboxy-prothrombin (DCP). C. Serum alpha-fetoprotein
(AFP) in c-Jun~Fra-2hep mice and
littermate controls over time. D. AFP, Mcm2 and Sox9
immunohistochemistry (IHC) in
c-Jun~Fra-2hep and control livers. Bar
= 100µm, tumors (T) are indicated by a dotted line and arrows point to
positive nuclei. E. qRT-PCR quantification of oncofetal,
stemness and senescence-associated genes in
c-Jun~Fra-2hep tumors and non-tumoral
(NT) liver areas compared to controls. F. Gp73 and Bex
immunoblot in livers extract from
c-Jun~Fra-2hep mice (non-tumoral and
tumors) and controls. G. Immunoblot for cell cycle-,
replicative stress- and DNA damage-related proteins in liver extracts
from c-Jun~Fra-2hep mice (non-tumoral
and tumors) and controls. H. γH2AX IHC in liver sections of
c-Jun~Fra-2hep mice and controls at 2
months and 9 of transgene expression (left) and quantification of
hepatocyte (hep) γH2AX-positivity at 2 months (right). Bar = 100µm,
tumors (T) are indicated by a dotted line and arrows point to positive
nuclei. Unless otherwise indicated, all data are from mice with 9 months
of transgene expression (off Dox at weaning). Gapdh and Vinculin are
used to control loading. Bars = means ±SEM. * p<0.05, ***
p<0.001 (t-test to controls).